Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
46 hedge funds and large institutions have $103M invested in Ibere Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
2% less capital invested
Capital invested by funds: $105M → $103M (-$1.65M)
4% less funds holding
Funds holding: 48 → 46 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$3.25M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.75M |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$1.1M |
| 4 |
D.E. Shaw & Co
New York
|
+$1,000K |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$981K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.39M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$1.96M |
| 3 |
CCM
Context Capital Management
Lajolla,
California
|
-$1.13M |
| 4 |
ICMH
Integrity Capital Management (HK)
Central,
Hong Kong
|
-$458K |
| 5 |
DFCM
Dark Forest Capital Management
San Juan,
Puerto Rico
|
-$224K |
IBER Hedge Fund Activity: Q2 2022 in Review
46 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q2 2022, worth a combined $103M — down 1.6% from $105M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IBER and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 6 added.
The largest buyer was Glazer Capital LLC, adding an estimated $3.25M. The largest seller was Citadel Advisors, cutting an estimated $5.39M.
- 46 institutional investors held Ibere Pharmaceuticals (IBER) as of Q2 2022, down from 48 in Q1 2022.
- Funds reported $103M of Ibere Pharmaceuticals stock for Q2 2022, down 1.6% quarter-over-quarter.
- 5 funds opened new Ibere Pharmaceuticals positions in Q2 2022 and 6 closed out, a net change of -1 holder.
- The largest Ibere Pharmaceuticals buyer in Q2 2022 was Glazer Capital LLC, an estimated $3.25M added.
- The largest Ibere Pharmaceuticals seller in Q2 2022 was Citadel Advisors, an estimated $5.39M sold.
Based on aggregated 13F filings for Q2 2022.